The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
Phase of Trial: Phase III
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Dexamethasone (Primary)
- Indications Ocular inflammation
- Focus Registrational; Therapeutic Use
- Sponsors EyePoint Pharmaceuticals; Icon Bioscience
- 28 Mar 2018 According to an EyePoint Pharmaceuticals media release, pSivida Corp. acquired Icon Bioscience and subsequently changed its name to EyePoint Pharmaceuticals.
- 28 Mar 2018 Results presented in the EyePoint Pharmaceuticals media release.
- 20 Apr 2015 According to an Icon Bioscience media release, results from this trial were presented at the 2015 Annual Symposium & Congress of the American Society of Cataract and Refractive Surgery (ASCRS) & American Society of Ophthalmic Administrators (ASOA).